A.I.-guided Chemo Halts Disease Worsening in Patient with mPRPC, Study Reports

A.I.-guided Chemo Halts Disease Worsening in Patient with mPRPC, Study Reports
An artificial intelligence (A.I.) platform called CURATE.AI may be used to determine the optimal doses of investigational therapy ZEN-3694 and Xtandi (enzalutamide) to be given to patients with metastatic castration-resistant prostate cancer (mCRPC). The approach led to a complete and durable halt of disease progression in a patient included in a Phase 1/2 trial. The research, “Modulating BET Bromodomain Inhibitor ZEN-3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform,” appeared in the journal Advanced Therapeutics. Cancer chemotherapy is typically administered at fixed doses. Despite being a standard for clinical care, this approach does not take into account the changing response to medications during the course of treatment, which affect its effectiveness and tolerability. Also, each patient responds to combination treatment differently, as drug synergy — medications working together to boost efficacy — is patient-specific. To address this limitation, the team, led by the National University of Singapore (NUS) conducted a one-year study at the UCLA Institute of Urologic Oncology. They developed CURATE.AI, which has been used to optimize liver transplant immunosuppression and tuberculosis therapy, among other indications. This A.I. platform intends to increase treatment effectiveness by rapidly identifying the doses of optimal medications. CURATE.AI uses the patient's own clinical data — including treatment doses and changes in tumor size, as well as blood levels of cancer biomarkers — to develop an individualized profile for the best possible treatment outcome. "As a patient's body and the cancer itself evolve during treatment, the CURATE.AI profi
Subscribe or to access all post and page content.